

PCTWORLD INTELLECTUAL PROPERTY
Organization


INTERNATIONAL APPLICATION PUBLISHED UNDER THE

WO 9605884A1

(51) International Patent Classification ⁶ : A61N 1/30, B65D 47/10		A1	(11) International Publication Number: WO 96/05884
			(43) International Publication Date: 29 February 1996 (29.02.96)
(21) International Application Number: PCT/US95/10897		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).	
(22) International Filing Date: 17 August 1995 (17.08.95)			
(30) Priority Data: 293,484 22 August 1994 (22.08.94) US			
(71) Applicant: IOMED, INC. [US/US]; Suite A, 1290 West 2320 South, Salt Lake City, UT 84119 (US).		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(72) Inventors: BECK, Jon, E.; 3445 East Del Verde Avenue, Salt Lake City, UT 84109 (US). LLOYD, Lindsay, B.; 1085 West 9000 South, West Jordan, UT 84088 (US). PETELENZ, Tomasz, J.; 2520 Blaine Avenue, Salt Lake City, UT 84108 (US).			
(74) Agent: SEELEY, David, O.; Workman, Nydegger & Seeley, 1000 Eagle Gate Tower, 60 East South Temple, Salt Lake City, UT 84111 (US).			

(54) Title: IONTOPHORETIC DELIVERY DEVICE WITH INTEGRAL HYDRATING MEANS**(57) Abstract**

The present invention provides methods and apparatus permitting rapid and thorough hydration of an initially dry hydratable matrix element (34) contained within an iontophoretic bioelectrode. The apparatus of the invention comprises a bioelectrode system (20) for iontophoretic delivery of medicaments having at least one hydratable matrix element (34) and associated removable hydration assembly (58). The preferred embodiment of the present invention comprises two hydratable matrix elements each having an associated removable hydration assembly and each being associated with an electrical current distribution element (24). The removable hydration assembly includes an initially sealed liquid-storage component (46) which maintains the desired hydrating liquid in isolation from the hydratable matrix element until such time as hydration is desired. At that time, the removable hydration assembly can be activated by the user through application of force to an extending tab (32) member attached to the sealed liquid-storage component thereby causing progressive unsealing of the sealed liquid-storage component and progressively depositing the hydrating liquid uniformly onto the entire surface of the hydratable matrix element. Following hydration of the matrix element, the spent hydration assembly can be withdrawn completely from within the bioelectrode system.



FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

IONTOPHORETIC DELIVERY DEVICE WITH INTEGRAL HYDRATING MEANS

BACKGROUND OF THE INVENTION

Technical Field

This invention relates to a bioelectrode system for iontophoretic delivery of medicaments.

Background Information

Iontophoretic delivery of medicaments has been found useful in a number of different applications including, for example, delivery of pilocarpine salts as a diagnostic test for cystic fibrosis and delivery of lidocaine hydrochloride to anesthetize a localized area prior to some minor surgical procedure such as wart removal.

Typically, systems for iontophoretic delivery of medicaments use two bioelectrodes, one positive and one negative, each placed in electrical contact with a portion of the skin or a mucosal surface of the body. Also typical is that each bioelectrode contains an electrolyte solution at least one of which contains ionized medicament. An electrical power source, such as a battery, is connected to the electrodes to complete the electrical circuit through the body. The charge of the ionized solution determines bioelectrode polarity such that, when current is supplied, the medicament ions migrate away from the electrode and are thereby delivered through the skin.

Some type of enclosure or other fluid-holding means is typically used to contain the ionized electrolyte or medicament solution such that a mechanism or structure on the enclosure is necessary to permit the introduction of solution thereunto. Such structure has typically included some type of orifice containing a plug into which a hypodermic needle or syringe canula may be inserted to allow delivery of the solution through the orifice into the interior of the enclosure, while preventing the outflow of the solution after it has been introduced into the enclosure. The requirement of such solution receiving mechanism or enclosure increases the cost of the bioelectrode system and gives rise to potential spillage and leakage of solution. Such spillage and leakage can result in an inoperative or defective device.

More recent bioelectrode systems have used hydrophilic polymers to form means for holding the medicament and electrolyte solutions. See, for example, the preformed gel body described in U.S. Pat. No. 4,383,529 issued to Webster, incorporated herein by reference. Although such pre-hydrated gel bodies may prevent leakage and spillage problems, there may still be stability and storage problems. To address these problems, bioelectrodes containing initially "dry," but hydratable, holding means for the medicament and electrolyte solutions have been developed. See, for example, the hydratable layers of hydrogel sheets described in Lloyd et al., U.S. Pat. No. 5,236,412, incorporated herein by reference.

In addition, efforts have been directed to developing bioelectrode systems containing initially dry, but hydratable, solution-holding components wherein the means for hydrating the components is also self-contained. Thus, for example, Haak et al., U.S. Pat. No. 5,288,289 and Gyory et al., published international patent application, WO 93/24177, both of which are incorporated herein by reference, disclose various self-contained means for releasing hydrating liquid from liquid-storage components and thereby hydrating the initially dry solution-holding components.

In certain embodiments of the Haak patent, the hydrating liquid-storage components comprise breakable capsules filled with the desired hydrating liquid which are positioned within a layer of material such that the liquid is isolated from the hydratable solution-holding components. Squeezing or flexing of the hydrating liquid-storage component breaks the capsules and releases the hydrating liquid. The hydrating liquid flows onto the electrical current distribution element and through preformed passageways to the hydratable solution-holding component. Optional wicking material is described to enhance rapid transfer of the liquid across the electrode conductor surface where the liquid can flow through the passageways to the hydratable solution-holding component.

It can be seen that the hydrating rate, the completeness of the fluid transfer, and the fluid distribution pattern is affected by the characteristics and properties of the separate elements which must be in fluid communication, i.e., the interposed electrical current distribution element material, the hydrating liquid-storage component material, the hydratable solution-holding component material, and the optional wicking material.

Other variables include the size, shape, and other characteristics of the flow through openings between the hydrating liquid-storage component and the hydratable solution-holding component, the distributional arrangement of the capsules within the hydrating liquid-storage component material, and even whether or not all of the capsules break or whether the encapsulized liquid is completely dispensed from the broken capsules. Moreover, inadvertent squeezing or flexing of the hydrating liquid-storage component could occur during manufacture, shipping, storing or handling of the device. Such an occurrence could break some or all of the hydrating liquid-filled capsules and cause premature hydration of the hydratable solution-holding component. Such premature hydration could result in an unusable or defective device.

Alternatively, the bioelectrode system disclosed in the Haak patent comprises separate components such that the hydrating liquid-storage component is covered by a removable liquid-impermeable sheet such that removal of the sheet exposes the hydrating liquid. The hydrating liquid-storage component is attached to one portion of the system. The hydratable solution-holding component is attached to a separate portion of the system. A user of the system removes the liquid-impermeable sheet to expose the hydrating liquid and then manually assembles the separate portions such that the hydrating fluid contacts, and thereby hydrates, the hydratable solution-holding component.

Alternatively, the system portions are not separate from each other but, rather, the portion attached to the hydrating liquid-storage component is positioned adjacent to the portion attached to the hydratable solution-holding component such that a folding over maneuver will cause contact of the hydratable solution-holding component with the exposed hydrating fluid. Yet another embodiment has the hydrating liquid-storage component and the hydratable solution-holding component attached to a first portion of the system while a second portion of the system contains pins for puncturing the hydrating liquid-storage component. In this embodiment, manual alignment and assembly of the first and second portions causes the pins to puncture the hydrating liquid-storage component and thereby release the fluid to hydrate the hydratable solution-holding component.

In the above-described devices, the need to manually assemble the separate system portions inhibits inadvertent hydration of the hydratable solution-holding component. Nevertheless, separate, or foldable, portions are more costly and cumbersome to use than a unitary device. Such devices also depend on proper assembly by the user. Mis-alignment or improper use could result in inefficient hydration.

As with the previously discussed Haak embodiments, the hydrating rate, the completeness of the fluid transfer, and the uniformity of fluid distribution in the above-described devices are also affected by the characteristics and properties of the individual components, i.e., the interposed electrical current distribution element material, the hydratable solution-holding component material, the hydrating liquid-storage component material, and the optional wicking material. The precision of the alignment of the system portions with each other will also be a factor. In addition, specifically for the device featuring puncturing pins to release the hydrating liquid, the variability in size and shape of the resultant torn or punctured openings created within the hydrating liquid-storage component material or between the hydrating liquid-storage component and the hydratable solution-holding component will affect the escape and dispensing of the hydrating liquid.

Approaches disclosed by Gyory et al. include a hydrating liquid-storage component which is separated from a hydratable solution-holding component by a liquid-impermeable sheet. Certain embodiments rely on packaging means to protect from inadvertent release of the hydrating liquid and to cause "automatic" hydration upon removal of the device from the package. The packaging means which effect "automatic" hydration include compression means to rupture or burst the liquid-impermeable sheet; blade means to puncture the liquid-impermeable sheet; and pull-tab means to rip or tear the liquid-impermeable sheet. An alternative embodiment attaches the pull-tab means, for ripping or tearing the liquid-impermeable sheet, to a release liner covering a skin contacting surface of the device. In this embodiment, removal of the release liner prior to placement on the patient "automatically" pulls the pull-tab means to rip or tear the liquid-impermeable sheet and thereby release the hydrating liquid. Like the Haak invention, Gyory also discloses liquid flow control means for directing the flow of

hydrating liquid through the breached liquid-impermeable sheet to the hydratable solution-holding component.

It can be seen that, in Gyory's devices, it is the liquid-impermeable sheet separating the hydrating liquid-storage component from the hydratable solution-holding component which is physically ruptured, punctured, or ripped. The material comprising the hydrating liquid-storage component, however, remains intact. After the liquid-impermeable sheet is breached and the hydrating liquid is released, the material which formed the now-depleted hydrating liquid-storage component remains positioned within the device. In the case of a ruptured or punctured sheet, all of the now-breached liquid-impermeable sheet material also remains entirely within the device. In the pull-tab embodiment, some of the sheet material is ripped or torn away and is removed from within the device with the attached pull-tab. Nevertheless, in all cases, a substantial portion of the liquid-impermeable sheet material as well as all of the hydrating liquid-storage component material remains within the device following the hydration process.

The rupturing, puncturing, or tearing of the liquid-impermeable sheet material exposes torn edges and, thus, inner layers, of the liquid-impermeable sheet including, for example, foil edges. The hydrating liquid-storage component material and the breached liquid-impermeable sheet material, including exposed torn inner layer edges, remain within the device. These no-longer needed materials could interfere with electrical current distribution. These materials also contact the now-hydrated solution-holding component such that deleterious communication with the solution is possible. For example, over long-term iontophoresis, i.e. many hours, materials such as exposed foil edges could corrode. Thus, it would be advantageous to be able to remove the materials associated with the hydrating liquid-storage component following the hydration process.

Both Haak and Gyory provide liquid-conveying pathways to distribute the hydrating liquid. Such liquid-conveying pathways, however, necessarily affect the transfer of the hydrating fluid because the rate and amount of fluid transferred is limited by the pathway configuration. It would, however, be advantageous to effect essentially uniform transfer of the hydrating fluid directly onto the surface of the hydratable reservoir element.

SUMMARY OF THE INVENTION

In accordance with the invention as embodied and broadly described herein, the apparatus of the invention comprises a bioelectrode system for iontophoretic delivery of medicaments having at least one hydratable matrix element and associated removable hydration assembly. The preferred embodiment of the present invention comprises two hydratable matrix elements each having an associated removable hydration assembly and each being associated with an electrical current distribution element. Typically, one matrix is associated with the positive electrical current distribution element and the other matrix is associated with the negative electrical current distribution element, although alternating current may also be utilized for certain applications.

The removable hydration assembly includes an initially sealed liquid-storage component which maintains the desired hydrating liquid in isolation from the hydratable matrix element until such time as hydration is desired. At that time, the removable hydration assembly can be activated by the user to cause progressive unsealing of the sealed liquid-storage component thereby progressively depositing the hydrating liquid uniformly onto the entire surface of the hydratable matrix element. This hydration process can be activated either prior to or following placement of the bioelectrode system on the patient's skin. Hydration following placement may be advantageous in that no fluid is lost through contact with other surfaces, such as the packaging material or the user's hands. In addition, the bioelectrode system may be more easily and securely positioned on the patient in the initial dry, rather than the hydrated, state.

Following hydration of the matrix element, the spent hydration assembly can be withdrawn completely from within the bioelectrode system thereby preventing further interaction with the remainder of the bioelectrode system.

The hydratable matrix elements and the associated hydration assemblies of the present invention may be conveniently attached to a multilaminate mounting element. The multilaminate mounting element may comprise one layer containing the positive and negative electrical current distribution elements. The multilaminate mounting element also may conveniently comprise another layer providing fixation means for attachment of the bioelectrode system to a body surface. Additionally, the multilaminate mounting

element could include other layers such as a moisture barrier layer, an insulating layer, and a sealant layer.

The bioelectrode system of the present invention comprises an electrical power source and electronic controller. These can be optionally positioned in either direct or remote communication with the integral unit. The electronic controller may be reusable or replaceable after a predetermined number of uses or time period. The remainder of the bioelectrode system may be disposable after, for example, a predetermined time period. The electrical power source is preferably a disposable battery integrally attached to the multilaminate mounting element.

BRIEF DESCRIPTION OF THE DRAWINGS

In the accompanying drawings, which represent the best mode presently contemplated for carrying out the present invention:

Figure 1 is a perspective top view of a preferred embodiment of the bioelectrode system of the present invention.

Figure 2 is a perspective bottom view of the preferred embodiment of Figure 1.

Figure 3 is a perspective view of the preferred embodiment of Figure 1 with certain components broken out and shown in order of attachment.

Figure 4 is a cross-section of a portion of the preferred embodiment taken along the line 4-4 of Figure 1 prior to activation of the hydration assembly.

Figure 5 is a cross-sectional view of the preferred embodiment corresponding to Figure 4 but illustrating the hydration process in progress.

Figure 6 is a cross-sectional view of the preferred embodiment corresponding to Figures 4 and 5 following completion of the hydration process.

Figure 7 illustrates a strip element of the preferred embodiment.

Figure 8 illustrates filling of the pocket member formed from portions of the strip element of the preferred embodiment.

Figure 9 illustrates the filled and sealed liquid-storage component of the preferred embodiment.

Figure 10 illustrates the hydration assembly of the preferred embodiment.

Figure 11 is a cross-sectional view of a portion of an alternative embodiment of the present invention shown prior to activation of the hydration assembly.

Figure 12 is a cross-sectional view of a portion of another alternative embodiment of the present invention shown prior to activation of the hydration assembly.

5 Figure 13 is a perspective top view of another alternative embodiment of the present invention.

Figure 14 is a perspective top view of a single electrode embodiment of the present invention.

10 DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention relates to bioelectrode systems for iontophoretic delivery of medicaments. Iontophoresis is recognized as a useful process for the non-invasive transdermal or transmucosal delivery of beneficial agents. The presently preferred bioelectrode system of the present invention provides an integral unit that can be
15 manufactured using conventional materials and techniques. Various components, such as the removable hydration assemblies, the hydratable matrix elements, the electronic controller, and the multilaminate mounting element incorporating the electronic distribution elements, can be conveniently manufactured separately and then delivered for final assembly into an integral unit. The integral bioelectrode unit of the present
20 invention provides a compact, lightweight and simple to use device which can be adapted for use with various ionic chemical agents, hereinafter usually referred to as "medicaments." The teachings contained herein should also be understood, however, as also having applicability to single bioelectrodes and associated hydration systems.

The bioelectrode system of the present invention is generally intended to contain
25 ionized medicament solution. A second hydratable matrix element is generally intended to contain a dispersive electrolyte solution. Initially, the matrix elements are "dry" such that the bioelectrode system can be stably stored and handled. The "dry" matrix elements are referred to as "hydratable" because they must be hydrated prior to use. Hydration is accomplished by means of a removable hydration assembly containing the desired
30 hydrating liquid. Thus, the dry matrices may contain a dry form of the desired medicament or electrolyte solution which is hydrated with an appropriate diluent or the

dry matrices may contain only support material which is hydrated with the appropriate medicament or electrolyte solution. It may also be possible to store and handle combinations of medicaments wherein some are stable in dry form and some are stable in hydrated form but the combination is not stable and must be kept separated prior to use. The stable dry medicaments can be stored in the dry matrix element and the stable hydrated medicaments can be stored in the hydrating fluid-storage component until the desired time of use.

Also integral to the presently preferred bioelectrode system of the present invention is a predetermined amount of hydrating liquid for each hydratable matrix element which is initially maintained in isolation from the hydratable matrix element. The present invention features an integral removable hydration assembly providing means for storing the hydrating liquid and dispensing the hydrating liquid onto the surface of the hydratable matrix element in a rapid and uniform manner at the time of iontophoresis. The hydration assembly is initially integral to the bioelectrode system of the present invention and comprises a predetermined amount of hydrating liquid isolated from the hydratable matrix element and stored within a sealed liquid-storage component. Following activation of the hydration assembly and completion of the hydration process, the entire hydration assembly is removable from within the bioelectrode system.

The presently preferred bioelectrode system is further designed to assure consistent dose control and even electrical current distribution with minimum power dissipation. Iontophoretic bioelectrode systems require an electrical power source. The electrical power source can be of any conventional type, although a compact, tamper-resistant, disposable battery which can be attached directly to the integral unit is preferred.

The bioelectrode system of the present invention can be easily applied to skin or mucosal body surfaces. The hydration process may be activated either prior to or following placement on the patient. Hydration following placement may be advantageous in that no fluid is lost through contact with other surfaces, such as the packaging material or the user's hands. In addition, the bioelectrode system may be more easily and securely positioned on the patient in the initial dry, rather than the hydrated, state. The compact and lightweight nature of the bioelectrode system permits

comfortable wear for relatively long periods of time and placement of the system under clothing, if desired. The non-invasive nature of iontophoretic delivery avoids problems associated with other modes of administration such as delayed and erratic oral absorption or the discomfort and risks associated with injections or indwelling catheters.

5 It is presently preferred that an electronic controller be provided to control the conduct of iontophoresis. The electronic controller is preferably capable of monitoring the bioelectrode system with regard to duration, strength, polarity, and time profile or wave form of electric current flow, total dose of medicament administered, rate and timing of administered doses, calculated patient-specific blood concentration ranges, and related data. Recording, storing, and retrieval of such data could also be features of the electronic controller. The electronic controller is preferably compact and lightweight such that it can be attached directly to the bioelectrode system during use by a patient. Because it is not a low cost item, however, a directly attached electronic controller should be removable so that it can be re-used. Alternatively, the electronic controller may be attached to the bioelectrode system via remote communication means, preferably wireless. The electronic controller is preferably battery-powered such that the bioelectrode system is entirely portable.

10 The electronic controller is preferably designed to be programmable to achieve desired rates of medicament administration. For example, the bioelectrode system of the present invention could be used to provide a non-invasive transdermal, iontophoretic drug delivery system for patient-controlled administration of an opioid analgesic for control of severe pain such as, for example, postoperative pain. Examples of suitable medicaments for this purpose would include salts of fentanyl or sufentanil. A particularly preferred medicament is fentanyl hydrochloride.

25 Advantages of patient-controlled analgesia observed with currently utilized intravenous delivery devices include improved management of pain, lower incidence of pain-related morbidity, more efficient use of narcotics such that lower total doses are possibly used, shortened hospital stays, earlier ambulation, and reduced costs as compared to other pain control methods. Because iontophoretic delivery is non-invasive, however, the problems and risks associated with prolonged intravenous administration, such as discomfort and potential infections, are avoided.

The method of using the bioelectrode system of the present invention for delivery of patient-controlled analgesia includes programming the electronic controller to provide a dose range and administration pattern suitable for the particular patient. This step is preferably performed by an appropriate medical care provider. The electronic controller would be programmed to provide continuous baseline delivery of drug with low level current for a predetermined period of time. Thus, the bioelectrode system of the present invention would deliver a predetermined, individualized dose of narcotic analgesic in a continuous manner to assure appropriate steady-state plasma level of the narcotic. In addition, the patient would be able to administer additional bolus doses of drug with high level current over short periods for treatment of breakthrough pain. A lock-out time range could be adjusted by the medical provider to individualize the dose and rate of administration of the bolus doses.

Additional safety features could also be included. For example, when used for patient-controlled analgesia administration, activation of the bolus drug administration will be accessible to the patient yet protected from inadvertent activation, the electronic controller will not allow for interchanging electrodes between patients during treatment, and detachment or re-attachment of the controller during treatment will not interfere with the lock-out time and sequencing of bolus doses to prevent administration of excessive bolus doses. The controller could also include a bioelectrode recognition feature for identifying a specific bioelectrode upon disconnection such that the possibility of reconnecting to a different device and thereby confusing two different treatment protocols is eliminated.

A feature of the bioelectrode system of the present invention is that the system is stored in an initially "dry" state to avoid problems associated with the manufacture, storage, handling, stability, and use of pre-hydrated bioelectrodes. Another feature of the present invention is provision of self-contained means for hydrating an associated hydratable matrix element, which hydrated matrix element will serve as a medicament or electrolyte solution reservoir during iontophoresis. The hydrating means includes a removable hydration assembly containing an initially sealed liquid-storage component which isolates a pre-determined quantity of hydrating liquid from the hydratable matrix element until such time as hydration is desired.

In addition to being simple to use, an advantage of the present invention is that the self-contained hydrating means cannot be inadvertently activated. Yet, when desired, user activation of the self-contained hydrating means results in rapid, complete, and uniform transfer of the desired hydrating liquid onto the entire surface of the hydratable matrix element.

In the accompanying drawings, Figure 1 illustrates a presently preferred integral bioelectrode system 20 constructed in accordance with the present invention. The bioelectrode system of the present invention is preferably a compact, lightweight, and largely disposable integral unit. First and second electrical current distribution elements 24a and 24b are preferably formed by depositing a conductive material onto a suitable backing thereby forming an electrode layer which can be incorporated within a multilaminate mounting element 22.

For example, the electrical current distribution elements may be formed of a metal foil, conductive carbon, or metal deposited or painted on a suitable backing. Examples of suitable materials include silver, zinc, silver/silver chloride, aluminum, platinum, stainless steel, gold, conductive carbon compounds and titanium. Alternatively, the electrical current distribution element layer could be formed of a conductive filler supported by a polymer matrix. The active surface area for each electrical current distribution element should preferably correspond to the surface area of the respective associated hydratable matrix element and should preferably comprise a surface area of about 8 cm².

In addition to providing support for the electrode layer comprising the first and second electrical current distribution elements 24a and 24b, the multilaminate mounting element 22 preferably serves as a support for various other components of the integral bioelectrode system. As illustrated in Figure 1, electronic controller 26 is preferably attached to the multilaminate mounting element. The overall size of multilaminate mounting element 22 is preferably no larger than about 60 cm² such that the bioelectrode system is compact and lightweight.

The multilaminate mounting element preferably comprises additional layers such as a foil layer, electrically insulated from the electrical current distribution element, to provide a moisture barrier to inhibit evaporation of solution from the hydrated matrix

elements during extended treatment periods. The insulation for the moisture barrier layer is preferably provided by an insulation layer comprising a polymer, such as a polyolefin/polyester composition. The multilaminate mounting element may also comprise a sealant layer, such as a polyolefin, applied to one surface. An example of a suitable flexible, heat sealable, barrier material suitable for use as the multilaminate mounting element is Techni-Lam Foil Lamination, #B-131 Prop, available from Technipaq, Inc., Crystal Lake, Illinois.

Also shown in Figure 1 is tab element 32 and cut-out slot 28. These features are described in detail below.

Figure 2 illustrates the preferred embodiment of Figure 1 viewed from the body-surface contacting side. In order to secure the bioelectrode system 20 to a patient's skin or mucosal surface, the body-contacting side of the preferred embodiment comprises fixation means. The fixation means preferably comprise a fixation layer 40 on the surface of the multilaminate mounting element. The portion of the fixation layer available for contacting the body surface should be of sufficient size to securely hold the bioelectrode system in place. The fixation layer can comprise, for example, a non-conducting adhesive layer. Such an adhesive layer is typically covered with a strippable release liner which is removed just prior to use.

Also shown in Figure 2 are optional porous cover membranes 36 which preferably enclose the body-contacting surface of the hydratable matrix element. The porous cover membrane is not intended to limit the flux of ions but rather is intended to inhibit bulk fluid flow from the hydrated matrix during periods when the bioelectrode system is not positioned in contact with a body surface. Accordingly, suitable materials for the cover membrane preferably have the following properties: high flow rate, flexibility, hydrophilicity, inertness, and toughness. Practical choices include expanded and supported acrylic, polysulfone, PVDF, PTFE, PP or nylon membranes treated to be hydrophilic. Alternatively, a thin mesh or weave comprised of any of the above-identified polymers or of polyester could be used. The presently-preferred material for the cover membrane is Versapor 10000 which comprises an expanded acrylic with fibrous nylon support having pores of 10 microns. Versapor 10000 is available from

Gelman Sciences, Membrane and Device Division, 600 South Wagner Road, Ann Arbor, Michigan.

Also illustrated in Figure 2 is a battery 30 which provides the electrical power source in the preferred embodiment. The battery is preferably a small, low-profile battery which is secured directly to the multilaminate mounting element 22. An example of a suitable battery is a flat-pac battery available from Gould Powerdex, Eastlake, Ohio.

The bioelectrode system of the present invention preferably permits the ionic medicament solution to be interposed between the appropriate electrical current distribution element and the patient's tissue such that the applied electrical current causes migration of the medicament ions into the tissue. Typically, one matrix is associated with the positive electrical current distribution element and the other matrix is associated with the negative electrical current distribution element, although alternating current may also be utilized for certain applications. As noted above, it is often disadvantageous to store a bioelectrode system with the medicament in hydrated form. Accordingly, it is preferred that medicament be provided in a dry form which permits hydration just prior to use.

The bioelectrode system of the present invention contains hydratable matrix elements and self-contained means for hydration of the matrices just prior to use. Figure 3 illustrates the preferred embodiment of the present invention with the components associated with one of the hydratable matrix elements 34 shown in broken out detail and in order of attachment to the multilaminate mounting element 22. A slot seal element 38 is a flap-type Reed seal that is positioned to align with the cut-out slot 28. Following hydration of the hydratable matrix and removal of the hydration assembly from within the bioelectrode system, slot seal element 38 advantageously functions to prevent the escape of medicament or electrolyte solution from the now-hydrated matrix element through the cut out slot during the period of iontophoresis.

It should be understood that the slot seal element could alternatively be aligned with the cut-out slot but positioned between the hydration assembly 58 and the hydratable matrix element 34 rather than between the hydration assembly 58 and the multilaminate mounting element 22. Moreover, in the event that a cut-out slot was alternatively formed in the cover membrane instead of the multilaminate mounting element, the slot seal

element could be positioned to function in the same manner and prevent communication between the hydrated matrix and the cut-out slot. Similarly, in an alternative embodiment, such as is illustrated in Figure 13, wherein the tab element protrudes from between other components rather than through a cut-out slot, the slot seal element could be positioned to function in the same manner and prevent communication between the hydrated matrix and the opening through which the tab member had protruded and the hydration assembly had been withdrawn.

The hydratable matrix elements are designed to provide a suitable support matrix for either a dry form of medicament or a dry form of a dispersive electrolyte. The hydrated volume for each matrix element is preferably less than one milliliter of drug or electrolyte fluid. Preferably, the hydratable matrix elements comprise a support material suitable for impregnation with the desired medicament. Suitable support materials would include, for example, a polyurethane sponge such as Foamex felted Z-90 firmness 2 polyurethane foam or Foamex ACQUELL hydrophilic foam manufactured by Foamex Foam Inc.; a nonwoven polyester such as REEMAY; or a fiber or cloth material.

It is generally desirable to load the hydratable matrix element with a hydrophilic thickener such as a high molecular weight polyethylene oxide (PEO), such as Polyox NF coagulant grade made by Union Carbide. Alternative hydrophilic materials include high molecular weight polyvinyl alcohol (PVA), poly-N-vinyl pyrrolidone (PVP), or other substituted pyrrolidones, polyacrylamide (PAAm), poly-N-isopropyl acrylamide (NIPPAm), polyhydroxyethyl methacrylate (PHEMA), or hydrophilic substituted HEMAs, polysaccharides such as agarose, hydroxyethyl cellulose (HEC), hydroxypropylmethyl cellulose (HPMC), hydroxypropyl cellulose (HPC), carboxymethyl cellulose (CMC), dextrans, modified starches, modified collagens, xanthan gum, guar gum, modified natural gums, partially neutralized polyelectrolytes such as polyacrylic acid, polyimides, and alginates. In some circumstances, copolymer mixtures of the foregoing may also be suitable. The preferred polymers, however, are non-ionic or non-electrolyte hydrophilic polymers such as PEO, PVP, PAAm, HPC and HEC, or copolymers of these, because these materials do not contain large numbers of ionizable moieties which would compete as charge carriers with the drug to be iontophoretically administered. Commercial forms of HPC are preferred such as Klucel HF NF. The

polymer is chosen so that fully dissolved thickener is viscous enough to remain within the hydrated matrix. For example, with the preferred Klucel HF NF, a concentration between 1 and 1.5% in the hydrated matrix has sufficient viscosity.

5 It may also be desirable to include various agents such as solvents, surfactants, wetting agents, or other excipients in the solution. A surfactant has been found particularly useful to assist in rapid hydration of the hydratable matrix element. Hence, it has been found useful to add Tween 20 nonionic surfactant (available from ICI America) to the hydratable matrix element. The addition of a surfactant such as Tween 20 has been found to aid the rate of wetting during hydration. Although for 10 purposes of brevity the following discussion is primarily directed to the use of Tween 20, it should be understood that other surfactants could also be used in place of Tween 20 in those situations where a surfactant is desired. Examples of other useful surfactants are Neodol 91-6 (a nonionic primary alcohol ethoxylate manufactured by Shell Chemical Co.); Tergitol 15-S-7 (a nonionic secondary alcohol ethoxylate manufactured by Union Carbide); Pluronic Poloxamer F68 or F127 made by BASF; and Duponol C or 15 Duponol XL (anionic sodium lauryl sulfates manufactured by Dupont Chemical Corp.). It is desirable that the surfactant be substantially nonionic, although small quantities of ionic moieties can be permitted.

20 In a presently preferred embodiment of hydratable matrix element, the thickener KLUCEL HF, manufactured by Aqualon Company, 1313 No. Market Street, Wilmington, De., and the surfactant TWEEN-20 are impregnated into a spin-laced rayon/polyester material, SONATRA 8423, manufactured by E.I. DuPont De Nemours & Co., Textile Fibers Dept., Wilmington, De. In dry form, this composition contains 15% Klucel and 15% Tween 20 by weight. Hydration of 8 cm² of this composition with 0.5 25 ml water forms a solution within the SONATRA which is about 1.5% KLUCEL and 1.5% TWEEN by weight.

30 As shown in Figure 3, the components associated with the hydratable matrix element in the preferred embodiment are the slot seal element 38, the removable hydration assembly 58, and the optional porous cover membrane 36. The porous cover membrane and slot seal element have been detailed above. The removable hydration

assembly will be better understood by reference to Figures 7-10, depicting formation of the hydration assembly and Figures 4-6, depicting the hydration process.

Accordingly, attention should now be directed to Figures 7, 8, 9, and 10, wherein the process for forming the hydration assembly of the preferred embodiment is illustrated in simplified detail. Figure 7 shows a strip element **42** which serves as a component of the hydration assembly of the presently preferred embodiment illustrated in Figures 1-6. The strip element material is liquid-impermeable and has a surface capable of being reversibly sealed to itself using a suitable sealing method such as heat sealing, crimping, or a pressure sensitive adhesive. For example, a suitable material would be a high barrier, heat seal peelable, puncture-resistant packaging material such as TPC-0760 manufactured by Tolas Health Care Packaging, Feasterville, Pennsylvania. TPC-0760 comprises polyester film, LD polyethylene, foil, ionomer, and a heat seal coating.

As shown in Figure 7, the strip element is preferably a single strip of suitable material. It should be understood, however, that the strip material could be formed in an alternative fashion without departing from the teachings set forth herein. One end of the strip element in Figure 7 has been folded to create an end flap **44** for use in attaching the strip element to the multilaminate mounting element, as will be described below. The strip element is further illustrated as having a first portion **42A** and a second portion **42B**.

Figure 8 shows the first portion **42A** of the strip element folded so as to face the second portion **42B** of the strip element. Also shown is another portion of the strip element designated **42D**. The edges of the first and second portions are sealed together such that a pocket member **45** having one open end is formed. In Figure 8, the sealed edges of the first and second portions are designated by reference numeral **42C**. Because the pocket member **45** must later be unsealed, seal **42C** must be accomplished in a manner which permits unsealing by operation of reasonable force, for example, 400-600 grams. Suitable strip materials and sealing methods were discussed above.

As shown in Figure 8, the desired hydrating liquid **52** is delivered through the open end of the pocket member **45**, schematically illustrated in Figure 8 by means of a dropper **50**. Once the desired hydrating liquid is delivered, the open end of the pocket member is sealed closed thereby forming a sealed liquid-storage component **46**. Figure 9 depicts this sealing by means of a dotted line **54** illustrating a chevron-shaped seal. The

5 advantage of using a chevron-shaped seal is that unsealing can begin substantially at a single point rather than along a broad area, thereby lessening the force required to commence opening of the liquid-storage member. It should be appreciated, however, that other patterns which ensure ease of unsealing could also be used. Although a chevron-shaped seal is preferred, it should be understood that a straight seal, or seal of other shape, could be used as long as the seal could be opened with reasonable force.

10 A completed hydration assembly 58 is illustrated in Figure 10. The third portion 42D of the strip element has been folded to a position aligned with the sealed liquid-storage component 46. As shown in Figure 10, because the third portion of the strip element is longer than the second portion, the third portion extends beyond the second portion thereby forming tab member 32. The result is a hydration assembly 58 which assumes a substantially flattened Z-shape configuration as best seen in Figure 10.

15 Referring once again to Figure 4, hydration assembly 58 is advantageously positioned within the bioelectrode system by affixing end flap 44 to the multilaminate mounting element 22 so as to dispose the sealed liquid-storage component 46 over the hydratable matrix element 34. Accordingly, activation of the hydration assembly permits the hydrating liquid 52 to be properly deposited upon the hydratable matrix element. The various components of the bioelectrode system are preferably assembled as shown in Figure 4 so as to form a cavity between the multilaminate mounting element 22 and the porous cover membrane 36. The hydration assembly 58 comprising the sealed liquid-storage component 46 with contained hydrating liquid 52, the slot seal element 38, and the hydratable matrix element 34 are positioned within the cavity. Tab member 32 extends through a cut-out slot 28 formed in the multilaminate mounting element to the exterior of the cavity. The cut-out slot 28 is more clearly seen in Figures 1 and 3.

20 The process of hydration is illustrated in progress in Figure 5. The arrow identified by reference numeral 48 in Figure 5 depicts the application of a force to the tab member 32 which results in movement of the tab member in the indicated direction. Movement of the tab member causes progressive unsealing of the attached liquid-storage component 46 within the cavity beginning at the chevron-shaped sealed end, not shown, as described above. As the liquid-storage component unseals, the portion of the strip element forming one side of the liquid-storage component is turned inside out such that

25

30

the wet surface, i.e., the surface which had been in contact with the contained hydrating liquid, is wiped against the surface of the hydratable matrix element. This progressive unsealing and inverting causes the hydrating fluid 52 to be continuously released and uniformly transferred along the length and width of the surface of the hydratable matrix element 34.

Figure 5 also illustrates the process of removing the hydration assembly 58 from within the cavity in progress. As the sealed liquid-storage component unseals, the strip element 42 is withdrawn from the cavity. Once the liquid-storage component is completely unsealed, the remaining portion of the strip element including the end flap 44, which is attached to the multilaminate mounting element, will remain within the cavity between the multilaminate mounting element and the hydratable matrix element. Further operation of the tab member will cause detachment of the end flap 44 such that the remaining portion of the strip element can be withdrawn from within the bioelectrode system. During this removal, the remaining portion of the strip element, one surface of which had formed an inner surface of the liquid-storage component contacting the hydrating liquid, will be wiped against the surface of the matrix element such that any remaining hydrating liquid is also transferred to the matrix element.

As can be seen in Figure 6, after the hydrating fluid has been completely transferred and the entire hydration assembly has been withdrawn, only the multilaminate mounting element 22, the now-hydrated matrix element 34, the porous cover membrane 36, and the slot seal element 38 remain within the illustrated portion of the preferred bioelectrode system. As described above, the slot seal element is positioned between the now-hydrated matrix element and the cut-out slot to prevent leakage of medicament or electrolyte solution through the cut-out slot.

The hydration process illustrated in Figures 4-6 can be summarized as follows. The initial "dry" state of the preferred bioelectrode system of the present invention is shown in Figure 4. The multilaminate mounting element 22 and the porous cover membrane 36 form a cavity surrounding the hydratable matrix element 34 and the sealed liquid-storage component 46 containing the hydrating liquid 52. The hydration assembly 58 is attached to the surface of the multilaminate mounting element by end flap 44. The tab member 32 protrudes from the cut-out slot 28 in the multilaminate

5 mounting element. The hydration process begins, as shown in Figure 5, when force is applied to tab member 32 causing the sealed liquid-storage component to become progressively unsealed commencing at the chevron-shaped sealed end, not shown. As the liquid-storage component is progressively unsealed, the hydrating liquid is progressively released directly onto the surface of the hydratable matrix element. In this manner, as the liquid-storage component is progressively opened, its interior surface, wetted by exposure to the stored hydrating liquid, is inverted, i.e., turned inside out, and is simultaneously wiped against the surface of the hydratable matrix element. This unsealing, opening, inverting, and wiping action ensures complete, rapid and substantially uniform distribution and transfer of the hydrating liquid across the entire surface of the hydratable matrix.

10 In addition to providing rapid, complete, and uniform transfer of the hydrating liquid onto the surface of the hydratable matrix element, operation of the tab member also progressively removes the entire hydration assembly from within the bioelectrode system. As the tab member is pulled, the liquid-storage component is substantially simultaneously unsealed, inverted, and withdrawn from the cavity. When the liquid-storage component is completely unsealed, further operation of the tab member causes the end flap 44 of the strip element to detach from the multilaminate mounting element such that the entire spent hydration assembly element can be removed from the bioelectrode system. Accordingly, Figure 6 illustrates the "hydrated" form of the preferred bioelectrode system.

15 It has been assumed in the foregoing discussion that medicament is stored in dry form as a component of the hydratable matrix element. It should be appreciated that medicament may alternatively be stored in hydrated form within the hydrating liquid-storage member. Another alternative would be to store one or more forms of medicaments in both the hydratable matrix element and within the hydrating liquid. Such a configuration may be particularly useful with multiple medicaments that may cross-react during storage or to increase concentrations at the time of use.

25 It should be understood that although Figures 1-6 depict a presently preferred embodiment of a bioelectrode system, other embodiments would come within the scope of the teachings set forth herein. For example, Figure 11 illustrates a cross-sectional view

30

of a portion of an alternative embodiment of the present invention at a time prior to hydration. It can be seen that Figure 11 corresponds to Figure 4 except that the position of the hydration assembly and the hydratable matrix element within the cavity are reversed. Accordingly, as in Figure 4, the initial "dry" state of the embodiment is illustrated wherein the multilaminate mounting element 22 and the porous cover membrane 36 form a cavity enclosing the hydratable matrix element 34 and the sealed liquid-storage component 46 containing the hydrating liquid 52. The hydration assembly 58 is attached to the porous cover membrane 36 by the end flap 44. The tab member 32 is seen to protrude from the cut-out slot 28 in the multilaminate mounting element. The slot seal element 38 is aligned with the cut-out slot and positioned between the hydration assembly 58 and the porous cover membrane 36. It should be understood that the hydration assembly could alternatively be attached to the multilaminate mounting element by the end flap and tab member could protrude from a cut-out slot formed in the porous cover membrane, if desired. Operation of the hydration means in this alternative embodiment proceeds in the manner illustrated for the preferred embodiment in Figures 5 and 6 with the only difference being that the relative positions of the hydration assembly and the hydratable matrix element are reversed.

Figure 12 is a cross-sectional view of a portion of yet another alternative embodiment of the present invention shown prior to hydration. This figure corresponds to Figure 4 except that the sealed hydrating liquid-storage component 46, rather than being formed by folding a first portion of the strip element to face a second portion of the strip element and sealing the edges of the portions together, is formed by sealing the edges of a first portion of the strip element to the facing surface of the multilaminate mounting element 22. The hydrating liquid is introduced into the pocket formed between the first portion of the strip element and the multilaminate mounting element and sealed closed in the manner described above for the preferred embodiment. Accordingly, as in Figure 4, the initial "dry" state of the embodiment is illustrated wherein the multilaminate mounting element 22 and the porous cover membrane 36 enclose the hydratable matrix element 34 and the alternative embodiment of the sealed liquid-storage component 47 containing the hydrating liquid 52. The hydration assembly 58 is attached to the multilaminate mounting element by the end flap 44 near the cut-out slot. The tab

member 32 protrudes from the cut-out slot 28 in the multilaminate mounting element. The slot seal element 38 is aligned with the cut-out slot and positioned between the multilaminate mounting element and the porous cover membrane. It should be understood that operation of the hydration means in this alternative embodiment proceeds in the manner illustrated for the preferred embodiment in Figures 5 and 6 with the only difference being that, once the liquid-storage component is completely unsealed, only the end flap 44 remains within the cavity between the multilaminate mounting element and the now-hydrated matrix element. As with the above-described embodiments, further operation of the tab member detaches the end flap such that the entire hydration assembly can be withdrawn completely from the cavity.

Figure 13 illustrates an alternative embodiment wherein tab member 32, rather than extending through a cut-out slot in the multilaminate mounting element, merely extends from between the multilaminate mounting element and the hydratable matrix element. Accordingly, rather than forming a cut-out slot within the multilaminate mounting element, the multilaminate mounting element and the hydratable matrix element are secured to each other in a manner providing an opening for protrusion of the tab member therethrough. It should also be understood that, although each hydration assembly is illustrated as having a separate tab member in the preferred embodiment, an alternative embodiment, as shown in Figure 13, could combine the tab members into one pull-tab member 33.

It should be understood that the hydration assembly disclosed above may be utilized within a single bioelectrode as well as within an integral bioelectrode system of the type illustrated. Figure 14 shows such a top view of single bioelectrode in accord with the present invention having a multilaminate mounting element 22 with a cut-out slot 28 through which the tab member 32 of the hydration assembly, not shown, protrudes. In this embodiment, a connector 60 serves to connect the hydratable matrix element, not shown, to an external electrical current, also not shown. The connector 60 is shown as a "nipple" type connector, however, it should be understood that other types of connectors would also be suitable.

The present invention may be embodied or utilized in other specific forms or manners without departing from its spirit or essential characteristics. The described

embodiments and methods are to be considered in all respects only as illustrative and not restrictive. The scope of the invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes which come within the meaning and range of equivalency of the claims are to be embraced within their scope.

5

What is claimed is:

0

5

0

5

0

1. A bioelectrode system for iontophoretically delivering medicament comprising:

an electrical power source for supplying an electrical current,
an electronic controller for controlling the supply of electrical current,
a first electrical current distribution element associated with the first side
of the electrical power source and a second electrical current distribution element
associated with the second side of the electrical power source;

a first hydratable matrix element associated with the first electrical current
distribution element and a second hydratable matrix element associated with the
second current distribution element;

first and second hydration means associated, respectively, with the first
and second hydratable matrix elements for hydrating said matrix elements, each
of said hydration means including a hydration assembly comprising:

a hydrating liquid and

a strip element comprising a sealed liquid-storage component and
an extending tab member wherein said sealed liquid-storage component
contains the hydrating liquid and is disposed with respect to the
associated hydratable matrix such that operation of the tab member causes
progressive unsealing of the liquid-storage component and progressive
deposit of the hydrating liquid upon said matrix element.

2. A bioelectrode system as defined in claim 1 further comprising a
multilaminate mounting element integral with the first and second electrical current
distribution elements, the first and second hydratable matrix elements, and the first and
second hydration assemblies.

3. A bioelectrode system as defined in claim 2 wherein the first and second
electrical current distribution elements comprise conductive material deposited onto a
suitable backing such as to form an electrode layer incorporated within the multilaminate
mounting element.

4. A bioelectrode system as defined in claim 2 wherein the multilaminate mounting element is further integrally attached to the electronic controller.

5 5. A bioelectrode system as defined in claim 1 further comprising fixation means to secure the bioelectrode system in a desired position on a patient's mucosal or skin surface.

6. A bioelectrode system as defined in claim 2 wherein the multilaminate mounting element further comprises a fixation layer.

0 7. A bioelectrode system as defined in claim 2 further comprising a first and second porous cover membrane integral with the multilaminate mounting element and positioned to enclose the body-contacting surface of the first and second hydratable matrix elements.

5 8. A bioelectrode system as defined in claim 2 wherein the multilaminate mounting element is further integrally attached to the electrical power source.

10 9. A bioelectrode system as defined in claim 2 wherein the multilaminate mounting element further comprises a first and second cut-out slot through which the extending tab members of the first and second hydration means protrude.

5 10. A bioelectrode system as defined in claim 9 further comprising a first and second slot seal element, each slot seal element integrally attached to the multilaminate mounting element in a position to prevent communication between the hydratable matrix elements and the associated cut-out slots following removal of the removable hydration means.

0 11. A bioelectrode system as defined in claim 1 wherein at least one of the hydratable matrix elements comprises support material impregnated with a dry form of

a medicament and the associated hydrating means comprises a pre-determined quantity of suitable diluent liquid.

5 12. A bioelectrode system as defined in claim 1 wherein at least one of the hydratable matrix elements comprises support material impregnated with a dry form of dispersive electrolyte and the associated hydrating means comprises a pre-determined quantity of suitable diluent liquid.

10 13. A bioelectrode system as defined in claim 1 wherein at least one of the hydratable matrix elements comprises dry support material and the associated hydrating means comprises a pre-determined quantity of medicament solution.

15 14. A bioelectrode system as defined in claim 1 wherein at least one of the hydratable matrix elements comprises dry support material and the associated hydrating means comprises a pre-determined quantity of dispersive electrolyte solution.

20 15. A bioelectrode system as defined in claim 2 wherein each hydration assembly comprises a strip element formed of a liquid-impermeable material having a surface capable of being reversibly sealed to itself.

25 16. A bioelectrode system as defined in claim 15 wherein each strip element further comprises a first and second portion folded so as to face each other and reversibly sealed along the edges to form a pocket member open at one end, which open pocket member is filled with hydrating liquid and sealed closed to form the sealed liquid-storage component.

 17. A bioelectrode system as defined in claim 16 wherein the first and second portions are sealed by heat welding.

30 18. A bioelectrode system as defined in claim 16 wherein the first and second portions are sealed with pressure sensitive adhesive.

19. A bioelectrode system as defined in claim 16 wherein the first and second portions are sealed by crimping.

5 20. A bioelectrode system as defined in claim 16 wherein the seal closing the open pocket member is applied in a chevron-shape to permit unsealing to commence at a single point.

10 21. A bioelectrode system as defined in claim 16 wherein the strip element further comprises a third portion folded into a position adjacent to the sealed liquid-storage component.

15 22. A bioelectrode system as defined in claim 21 wherein the first, second, and third portions of the strip element are foldably positioned in a substantially z-shaped configuration.

23. A bioelectrode system as defined in claim 21 wherein the third portion is longer than the second portion such that the third portion extends beyond the sealed liquid-storage component thereby forming the attached tab member.

20 24. A bioelectrode system as defined in claim 23 wherein each strip element further comprises an end flap.

25 25. A bioelectrode system as defined in claim 24 wherein each end flap is detachably attached to the multilaminate mounting element.

26. A bioelectrode system as defined in claim 25 wherein each hydration assembly is positioned between the multilaminate mounting element and the associated hydratable matrix element.

27. A bioelectrode system as defined in claim 25 wherein each hydratable matrix element is positioned between the associated hydration assembly and the multilaminate mounting element.

5 28. A bioelectrode system as defined in claim 15 wherein each strip element further comprises a first portion positioned adjacent to a portion of the surface of the multilaminate mounting element and reversibly sealed along the edges of the first portion so as to form a pocket member open at one end, which open pocket member is filled with hydrating liquid and sealed closed to form the sealed liquid-storage component.

10 29. A bioelectrode for iontophoretically delivering medicament comprising:
a first electrical current distribution element associated with the first side of an electrical power source and a second electrical current distribution element associated with the second side of the electrical power source;

15 a first hydratable matrix element associated with the first electrical current distribution element and a second hydratable matrix element associated with the second current distribution element;

20 first and second hydration means associated, respectively, with the first and second hydratable matrix elements for hydrating said matrix elements, each of said hydration means including a hydration assembly comprising:

a hydrating liquid and

25 a strip element comprising a sealed liquid-storage component and an extending tab member wherein said sealed liquid-storage component contains the hydrating liquid and is disposed with respect to the associated hydratable matrix such that operation of the tab member causes progressive unsealing of the liquid-storage component and progressive deposit of the hydrating liquid upon said matrix element.

30 30. A bioelectrode for iontophoretically delivering medicament comprising:
an electrical current distribution element associated with an electrical power source;

a hydratable matrix element associated with the electrical current distribution element;

hydration means associated with said hydratable matrix element for hydrating said matrix element, said hydration means including a hydration assembly comprising:

a hydrating liquid and

a strip element comprising a sealed liquid-storage component and an extending tab member wherein said sealed liquid-storage component contains the hydrating liquid and is disposed with respect to the associated hydratable matrix such that operation of the tab member causes progressive unsealing of the liquid-storage component and progressive deposit of the hydrating liquid upon said matrix element.

31. An integral bioelectrode system for iontophoretically delivering medicament comprising:

an electrical power source for supplying an electrical current,

an electronic controller for controlling the supply of electrical current,

a first electrical current distribution element associated with the first side of the electrical power source and a second electrical current distribution element associated with the second side of the electrical power source wherein the current distribution elements are deposited onto a backing material to form a layer incorporated into a multilaminate mounting element;

a first hydratable matrix element associated with the first electrical current distribution element and a second hydratable matrix element associated with the second current distribution element;

first and second porous cover membranes, each said porous cover membrane associated with one hydratable matrix element and attached to the multilaminate mounting element in a position to enclose the hydratable matrix element between the multilaminate mounting element and the porous cover membrane;

first and second hydration means associated, respectively, with the first and second hydratable matrix elements for hydrating said matrix elements, each of said hydration means including a hydration assembly comprising:

a hydrating liquid and

a strip element comprising an end flap detachably attached to the multilaminate mounting element, a sealed liquid-storage component containing the hydrating liquid, and an extending tab member wherein said tab member protrudes through a cut-out slot in the multilaminate mounting element and said sealed liquid-storage component is disposed with respect to the associated hydratable matrix such that operation of the tab member causes progressive unsealing of the liquid-storage component and progressive deposit of the hydrating liquid upon said matrix element.

32. A hydration assembly for use in hydrating a hydratable matrix element of an iontophoresis bioelectrode, said hydration assembly comprising:

a hydrating liquid and

a strip element comprising a sealed liquid-storage component containing the hydrating liquid, and an extending tab member wherein said sealed liquid-storage component is disposed with respect to the associated hydratable matrix such that operation of the tab member causes progressive unsealing of the liquid-storage component thereby progressively depositing the hydrating liquid upon said matrix element.

33. A hydration assembly as defined in claim 32 wherein the strip element comprises a liquid-impermeable material having a surface capable of being reversibly sealed to itself.

34. A hydration assembly as defined in claim 33 wherein the strip element further comprises a first and second portion folded so as to face each other and reversibly sealed along the edges to form a pocket member open at one end, which open pocket

member is filled with hydrating liquid and sealed closed to form the sealed liquid-storage component.

5 35. A hydration assembly as defined in claim 34 wherein the first and second portions are sealed by heat welding.

 36. A hydration assembly as defined in claim 34 wherein the first and second portions are sealed with pressure sensitive adhesive.

0 37. A hydration assembly as defined in claim 34 wherein the first and second portions are sealed by crimping.

 38. A hydration assembly as defined in claim 34 wherein the seal closing the open pocket member is applied in a chevron-shape to permit unsealing to commence at
5 a single point.

 39. A hydration assembly as defined in claim 34 wherein the strip element further comprises a third portion folded into a position adjacent to the sealed liquid-storage component.

0 40. A hydration assembly as defined in claim 39 wherein the first, second, and third portions of the strip element are foldably positioned in a substantially z-shaped configuration.

5 41. A hydration assembly as defined in claim 39 wherein the third portion is longer than the second portion such that the third portion extends beyond the sealed liquid-storage component thereby forming the attached tab member.

0 42. A hydration assembly as defined in claim 41 wherein the strip element further comprises an end flap.

43. A method for hydrating a hydratable matrix element of an iontophoresis bioelectrode, said method comprising steps of:

5 providing an iontophoresis bioelectrode having an integral hydration assembly in association with a hydratable matrix element, said hydration assembly comprising a hydrating liquid and a strip element comprising a sealed liquid-storage component containing said hydrating liquid, said liquid-storage component having an attached extending tab member;

10 positioning the hydration assembly adjacent the hydratable matrix element;

15 applying force to the extending tab member such that the attached sealed liquid-storage component is thereby progressively unsealed and the hydrating fluid is progressively deposited upon said matrix element; and


20 applying additional force to the extending tab member such that the hydration assembly is removed from integral attachment to the iontophoresis bioelectrode.

25

30

35

2/7



3/7




FIG. 4




FIG. 5




FIG. 6

4/7




FIG. 7




FIG. 8

5/7




FIG. 9




FIG. 10

6/7




FIG. 11




FIG. 12

7/7




FIG. 13




FIG. 14

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/10897

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61N 1/30; B65D 47/10
US CL : 222/541.6; 604/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : D24/189; 222/541.6; 383/210, 211; 604/20, 87, 890.1; 607/153

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
NONE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US, A, 5,310,404 (GYORY ET AL) 10 May, 1994, see entire disclosure.	1-6, 8-15, 28-33, 43
X --- Y	US, A, 2,702,146 (E. H. LAND) 15 February 1955, see entire document.	32-35, 39-43 ----- 36, 37
X --- Y	US, A, 4,941,574 (MEEHAN) 17 July 1990, see entire document.	32-35, 38, 39 ----- 36, 37
Y	US, A, 3,754,700 (BONK) 28 August 1973, see corrugated (crimped) sealing.	37

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A		document defining the general state of the art which is not considered to be part of particular relevance
* E		earlier document published on or after the international filing date
* L		document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
* O		document referring to an oral disclosure, use, exhibition or other means
* P		document published prior to the international filing date but later than the priority date claimed
	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
	* A	document member of the same patent family

Date of the actual completion of the international search
12 DECEMBER 1995

Date of mailing of the international search report
11 JAN 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Authorized officer
Mark Bockelman
MARK BOCKELMAN

Facsimile No. (703) 305-3230

Telephone No. (703) 308-2112

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/10897

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	GB, A, 2 066 208 A (SANDERS) 08 July 1981, see pressure sensitive adhesive.	36

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/10897

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US95/10897

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1.

Group I, claims 1-31 and 43, drawn to a bioelectrode and method of use.

Group II, claims 32-42, drawn to a hydration assembly.

Groups I and II, the inventions listed as these groups do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The special technical feature being a hydration assembly in combination with a hydrated matrix is not positively recited in Group II.

THIS PAGE BLANK (USPTO)